Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer therapeutics - EpiCept Corporation

Drug Profile

Research programme: anticancer therapeutics - EpiCept Corporation

Alternative Names: BCH 19746; BCH 23540; CV 2105; CV 58151; EPC 2105; EPC 58151; MX 116407; MX 2105; MX 58151

Latest Information Update: 17 Mar 2008

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiCept Corporation
  • Class Nitriles
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Solid tumours

Most Recent Events

  • 17 Mar 2008 Discontinued - Preclinical for Cancer in USA (IV)
  • 17 Mar 2008 Discontinued - Preclinical for Solid tumours in Canada (IV)
  • 05 Oct 2006 EpiCept has filed an IND with the US FDA for EPC 2407 for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top